Last reviewed · How we verify
Sulfentanil
Sulfentanil is a Small molecule drug developed by Henan Provincial People's Hospital. It is currently in Phase 1 development for General anesthesia, Postoperative pain.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Sulfentanil |
|---|---|
| Sponsor | Henan Provincial People's Hospital |
| Target | Solute carrier family 22 member 1, Delta-type opioid receptor, Kappa-type opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | Phase 1 |
Approved indications
- General anesthesia
- Postoperative pain
Common side effects
Key clinical trials
- Effects of Different Drugs for Glottic Atomization on Postoperative Sore Throat After Thyroid Surgery (PHASE4)
- Intercostal Nerve Cryoablation Versus Epidural Analgesia for Nuss Repair of Pectus Excavatum (NA)
- Cardiac Index and General Anesthesia Without Opioid. (PHASE2, PHASE3)
- Oliceridine Versus Sufentanil for Postoperative Nausea in Cerebellopontine Angle Surgery (NA)
- The Efficacy and Safety of Liposomal Bupivacaine for Transversus Abdominis Plane Block in Relieving Postoperative Pain After Laparoscopic Surgery (NA)
- The Efficacy and Safety of Liposomal Bupivacaine for Transversus Abdominis Plane Block in Relieving Postoperative Pain After Laparoscopic Surgery in Gynecologic Oncology (NA)
- The Efficacy and Safety of Liposomal Bupivacaine in Relieving Postoperative Pain After Laparoscopic Surgery (NA)
- Comparison of Anesthetic Techniques for Early Recovery After Ankle Arthroscopy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sulfentanil CI brief — competitive landscape report
- Sulfentanil updates RSS · CI watch RSS
- Henan Provincial People's Hospital portfolio CI
Frequently asked questions about Sulfentanil
What is Sulfentanil?
What is Sulfentanil used for?
Who makes Sulfentanil?
What development phase is Sulfentanil in?
What does Sulfentanil target?
Related
- Target: All drugs targeting Solute carrier family 22 member 1, Delta-type opioid receptor, Kappa-type opioid receptor
- Manufacturer: Henan Provincial People's Hospital — full pipeline
- Therapeutic area: All drugs in Pain
- Indication: Drugs for General anesthesia
- Indication: Drugs for Postoperative pain
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing